Navigation Links
The Deal Names Abbott Top Dealmaker for Third Consecutive Year

The Deal Names Abbott Top Dealmaker for Third Consecutive Year -- ABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Magazines, Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Awards Click to view news release full screen  

The Deal Names Abbott Top Dealmaker for Third Consecutive Year


Awards Recognize Industry-Leading Companies That Demonstrate Effective Strategic Use of Mergers and Acquisitions Over Past Three Years

ABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the third consecutive year.  The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective and consistent use of acquisitions and divestitures since January 2007.  

Over the past 24 months, Abbott has successfully executed on a number of strategic acquisitions that have enhanced the company's diversity, geographic reach and pipeline, and positioned the company for leadership in new, fast-growing markets.  Recently, the company completed its acquisition of Piramal Healthcare Solutions, bringing immediate market leadership in India, the world's second-fastest growing pharmaceutical market.  

"Abbott is honored to again be recognized by The Deal for our track record of acquisitions," said Miles D. White, chairman and chief executive officer, Abbott.  "In 2010, Abbott has successfully executed on a series of transactions to establish a leading presence in emerging markets, enhance its pharmaceutical pipeline and capitalize on global growth opportunities to drive continued top-tier performance."

In 2010, Abbott has:

  • Acquired Solvay Pharmaceuticals, complementing and diversifying its pharmaceutical portfolio and expanding Abbott's presence in key global emerging markets.
  • Purchased Facet Biotech, adding innovative oncology and neuroscience compounds to existing research expertise.
  • Announced a licensing agreement with Zydus Cadila to promote a portfolio of pharmaceutical products in 15 high-growth emerging markets.
  • Acquired a novel investigational biologic compound to treat chronic pain, enhancing Abbott's early-stage pharmaceutical pipeline.
  • Announced a collaboration with Neurocrine and Pierre Fabre to develop and commercialize treatments for endometriosis and oncology, respectively.

  • The Deal's readers rated Abbott best on the award criteria: choice of targets and strategy; price paid (or received) compared to value; execution, including integration; and overall quality of the deal team.  Companies considered for the survey have a market capitalization of $5 billion or more as of Dec. 31, 2009, closed the highest number and value of transactions and generated the largest increase in market capitalization over a three-year period ended Dec. 31, 2009.  

    About The Deal LLCThe Deal LLC ( is a diversified media and information company. We report, analyze and disseminate business and financial news and data that offer fresh insights on the deal economy, a set of interrelated activities, focused on dealmaking of all kinds, whose purpose is to generate corporate and capital growth in a continually changing global market. We serve the global deal community – corporate and financial dealmakers, advisers and institutional investors – with The Deal Pipeline, a transaction information service, and The Deal magazine, a business and financial magazine, website and event brand. The Deal LLC, a privately held company, is owned by private investment funds sponsored by Wasserstein & Co. LP.  

    About AbbottAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.  

    Abbott's news releases and other information are available on the company's Web site at


    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
    2. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
    3. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
    4. FierceBiotech Names Obesity Company Gelesis to Fierce 15 List of Top Emerging Biotech Companies
    5. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
    6. INC. 5000 Names ClinixMIS for Third Time
    7. SL Industries Names Louis J. Belardi Chief Financial Officer
    8. BayCare Health System Names Tim Thompson Chief Information Officer
    9. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
    10. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
    11. Ikaria® Names New Chief Financial Officer
    Post Your Comments:
    (Date:10/13/2015)... , Oct. 13 2015 ... addition of the "US & European ... Countries (2010-2021)" report to their offering. ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ...
    (Date:10/13/2015)... -- Graduate students across the country, with an interest ... have the opportunity to learn about a lesser-known ... and development process. Eli Lilly and Company (NYSE: ... from academic institutions to create an elective graduate ... Development."  Lilly will formally unveil the eLearning course ...
    (Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... California (PRWEB) , ... October ... ... launched Postnatal Omega-3, a first-of-its kind product that targets the unique health ... Postnatal Omega-3” of the American Pregnancy Association ( ), utilizes Nordic ...
    (Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra Health ... 59,000 emergency department visits per year, today announced the successful and rapid deployment ... clinical, operational and financial outcomes. , In less than four days, ...
    (Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, ... IV sedation dentistry for more than 5 years. A leading cause of emergency ... painful if treatment is not timely. , Sedation dentistry provides an ...
    (Date:10/13/2015)... ... 2015 , ... World Patent Marketing , a vertically integrated manufacturer and ... helps people in clearing snow away from the streets and driveways. , "The Snowplowing ... year," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
    (Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN report published ... a teammate accidentally elbowed him in the left eye during the first day of ... one of a series of setbacks, including a knee injury that has interfered with ...
    Breaking Medicine News(10 mins):